Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 889 posts found.

Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera

February 4, 2020
Manufacturing and Production, Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for …

News

Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

January 15, 2020
Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …

News
biogen_austria_238

Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

News
shutterstock_38078521

Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma

January 7, 2020
Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …

News

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

News

Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients

December 16, 2019
Sales and Marketing Pfizer, Vyndaqel, pharma

Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …

News

Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

December 9, 2019
Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …

News
pfizer_building_logo1_19

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

November 28, 2019
Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …

News
shutterstock_79370437

New ICER report reveals most cost-effective rheumatoid arthritis therapies

November 27, 2019
Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …

News

Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023

November 18, 2019
Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma

Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb),  its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,   …

News
shutterstock_273326141

Mylan and Upjohn merger will create a new entity: Viatris

November 13, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Pfizer, Upjohn, Viatris, pharma

The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has …

News

Pfizer’s tofacitinib hits main goal in Phase 3 juvenile idiopathic arthritis study

November 12, 2019
Manufacturing and Production, Research and Development Pfizer, pharma, tofacitinib

Pfizer has lifted the lid on new Phase 3 data exploring the efficacy of tofacitinib in the treatment of juvenile …

News
bavencio

Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

November 8, 2019
Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …

News
credit_-_daniel_leal-olivas-afp

Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer

October 29, 2019
Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …

News

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

October 14, 2019
Research and Development, Sales and Marketing Pfizer, abrocitinib, atopic dermatitis, pharma

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024